Real-world data suggest #MS patients with stable disease who switch to another IFN-beta therapy are at greater risk of flares than patients on IFN-beta who do not switch https://t.co/5F2HXLNPVT
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
RT @GavinGiovannoni: This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interfer…
This paper is why we need to make DMT switching and stopping criteria evidence-based. MSers who are stable on interferon therapy show better outcomes when staying on the same therapy than switchers. Why switch or stop if you are a responder? #ClinicSpeak h
RT @ChronicRights: #Multiplesclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy ... -…
#Multiplesclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy ... - https://t.co/X9QsRVT9ap
#Multiplesclerosis patients who are stable on interferon therapy show | CEOR https://t.co/b3jPL3hxgB